PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ezetimibe - Lipid modification

PAD Profile : Ezetimibe - Lipid modification

Keywords :
primary hypercholesterolaemia, high cholesterol, raised cholesterol, familial hypercholesterolaemia, lipid-lowering, lipid lowering
Brand Names Include :
Ezetrol

Traffic Light Status

Status 1 of 1.

Status :
Green
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
03 September 2014
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
People with primary hypercholesterolaemia should be considered for ezetimibe treatment in line with TA385 (formerly TA132 superceded by TA385 in Feb 2016) - see below

Associated BNF Codes

02. Cardiovascular System
02.12.00. Lipid-regulating drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More